Evidence map›Paper›PMID 35978141›Full record

ArticleJournal of molecular modeling2022

Pharmacophore-based virtual screening from phytocannabinoids as antagonist r-CB1.

Lenir C Correia, Jaderson V Ferreira, Henrique B de Lima, Guilherme M Silva, Carlos H T P da Silva, Fábio A de Molfetta, Lorane I S Hage-Melim

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of molecular modeling, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Lenir C CorreiaLaboratory of Pharmaceutical and Medicinal Chemistry (PharMedChem), Federal University of Amapá, Rod. JK, Km 02, Macapá, Brazil.
Jaderson V FerreiraLaboratory of Pharmaceutical and Medicinal Chemistry (PharMedChem), Federal University of Amapá, Rod. JK, Km 02, Macapá, Brazil.
Henrique B de LimaLaboratory of Pharmaceutical and Medicinal Chemistry (PharMedChem), Federal University of Amapá, Rod. JK, Km 02, Macapá, Brazil.
Guilherme M SilvaComputational Laboratory of Pharmaceutical Chemistry, Department of Pharmaceutical Sciences, School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil.
Carlos H T P da SilvaComputational Laboratory of Pharmaceutical Chemistry, Department of Pharmaceutical Sciences, School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil.
Fábio A de MolfettaLaboratório de Modelagem Molecular, Federal University of Pará, Belém-PA, Brazil.
Lorane I S Hage-MelimLaboratory of Pharmaceutical and Medicinal Chemistry (PharMedChem), Federal University of Amapá, Rod. JK, Km 02, Macapá, Brazil. loranehage@gmail.com.
Universidade Federal do Amapá · BRUniversidade de Ribeirão Preto · BRUniversidade de São Paulo · BRUniversidade Federal do Pará · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Search for new pharmacological alternatives for obesity is based on the design and development of compounds that can aid in weight loss so that they can be used safely and effectively over a long period while maintaining their function. The endocannabinoid system is related to obesity by increasing orexigenic signals and reducing satiety signals. Cannabis sativa is a medicinal plant of polypharmaceutical potential that has been widely studied for various medicinal purposes. The in silico evaluation of their natural cannabinoids (also called phytocannabinoids) for anti-obesity purpose stems from the existence of synthetic cannabinoid compounds that have already presented this result, but which did not guarantee patient safety. In order to find new molecules from C. sativa phytocannabinoids, with the potential to interact peripherally with the pharmacological target cannabinoid receptor 1, a pharmacophore-based virtual screening was performed, including the evaluation of physicochemical, pharmacokinetic, toxicological predictions and molecular docking. The results obtained from the ZINC

Indexed as

CannabinoidsMolecular Dynamics SimulationHumansMolecular Docking SimulationZincCannabinoidsZincMolecular dockingMolecular DynamicsNatural cannabinoidsrCB1 peripheralsStructure–activity relationshipVirtual Screening

Identifiers

PMID35978141
OpenAlexW4292342909

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.